dokumendiregister.ee
OtsingAsutusedMCP
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel
Otsing›Sotsiaalministeerium
Muu lepingAvalik

Leping

Sotsiaalministeerium · 13. jaanuar 2021
Viit
1.8-2/1311-1
Registreeritud
13. jaanuar 2021
Dokumendi liik
Muu leping
Funktsioon
1.8 Finantsplaneerimine ja raamatupidamisarvestus
Sari
1.8-2 Lepingud (töövõtt ja käsundus juriidiliste isikutega, koostöölepe kulude hüvitamiseks, haldus, liising, üür-rent, kindlustus, müük, litsentsid, ost, varaline vastutus, varakasutus, andmevahetus) koos aktidega
Toimik
1.8-2/2023
Vastutaja
Aili Petti

Failid

  • 📎JTC2021 MoU SIGN.pdf5519 KB

Sisu (failidest)

EJP RD JTC 2021: MoU European Joint Programme on Rare Diseases (EJP RD) Call for Proposals 2021 "Social sciences and Humanities Research to improve health care implementation and everyday life of people living with a rare disease” Memorandum of Understanding (MoU) on International Cooperation in Research Funding within the Framework of the EJP on Rare Diseases JTC 2021 Established between the following Participants: • Austrian Science Fund (FWF), Austria • Research Foundation Flanders (FWO), Belgium, Flanders • Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, Wallonia-Brussels Federation • Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada • Ministry of Social Affairs (MOSAE), Estonia • French National Research Agency (ANR), France • Federal Ministry of Education and Research (BMBF), Germany • National Research, Development and Innovation Office (NKFIH), Hungary • Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel • Italian Ministry of Health (MoH-IT), Italy • Tuscany Region (RT/TuscReg), Tuscany (Italy) • Research Council of Lithuania (LMT), Lithuania • National Research Fund (FNR), Luxembourg • National Centre for Research and Development (NCBR), Poland • Slovak Academy of Sciences (SAS), Slovakia • National Institute of Health Carlos III (ISCIII), Spain • Swiss National Science Foundation (SNSF), Switzerland 1 EJP RD JTC 2021: MoU • The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey • The French National Institute of Health and Medical Research (INSERM), France (will provide dedicated funding only to Patient Advocacy Organisations). 2 EJP RD JTC 2021: MoU INTRODUCTION There are at least 7000 distinct rare diseases, the great majority being of genetic origin. Although individually rare, taken together rare diseases affect at least 26-30 million people in Europe. Moreover, they represent a major issue in health care: a large number of these diseases have an early or very early onset and/or lead to a significant decrease of life expectancy. Moreover, most of them cause chronic illnesses with a large impact on quality of life and the health care system. Therefore, research on rare diseases is needed to provide knowledge for prevention, diagnosis, better care and everyday life improvement for patients. Yet, research is hampered by lack of resources at several levels: (1) Few scientists work on any given specific disease, (2) There are few patients per disease and they are scattered over large geographic areas, causing difficulties to assemble the necessary cohorts, (3) Existing databases and bio-material collections are usually local, small, and not accessible or standardized, (4) The complex and multiple problematics of these diseases require interdisciplinary cooperation to improve everyday life and care. Health is more than bioscience and medicine. Health also strongly relies on adequate social, psychological, cultural and historical resources. Care is more than healthcare: it is “the provision of what is necessary for the health, welfare, maintenance, and protection of someone or something”. Social sciences and Humanities (SSH) help understanding all dimensions of health and care: human condition, suffering, personhood, our responsibility to each other, implementation within cultural and social contexts. Therefore, SSH research in the field of rare diseases is of crucial importance to help better understanding and better implementation of solutions for those living with a rare disease. The specificities of rare diseases - limited number of patients per disease, scarcity of relevant knowledge and expertise, and fragmentation of research - single them out as a distinctive domain of very high European added-value. Rare diseases are therefore a prime example of a research area that necessitates collaboration/coordination on a transnational scale. In this context, the European Joint Programme on Rare Diseases (EJP RD) has successfully implemented two Joint Transnational Calls since 2019 to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC). These actions are following the ten Joint Transnational Calls for rare diseases research projects launched previously by the ERA- Net E-Rare since 2006. The aim of the call is in compliance with the vision and goals set by the International Rare Diseases Research Consortium (IRDiRC) which fosters international collaboration in rare diseases research. Under the umbrella of the EJP RD the above listed Participants decided to open the joint call for funding multilateral research projects on rare diseases (JTC 2021) whose details are agreed by the Participants as stated below. 3 EJP RD JTC 2021: MoU NOW, THEREFORE, THE PARTICIPANTS HAVE REACHED THE FOLLOWING UNDERSTANDING: 1. PURPOSE OF THIS MoU The aim of this Memorandum of Understanding (MoU) is to establish the principles and procedures to be adopted by all Parties in the Joint Transnational Call JTC 2021: • Launching a common call for proposals • Receiving collaborative proposals • Setting up a common evaluation and selection procedure • Providing funding for the proposals selected according to the final ranking list. 2. CONTENT OF THE CALL The Participants will launch a transnational programme on "Social sciences and Humanities Research to improve health care implementation and everyday life of people living with a rare disease” which will be jointly managed and financed by the Participants that are members of the EJP RD, according to their respective legal framework and regulations. The programme will be implemented by a call for proposals to be launched and processed in 2020-2021. The call will be opened simultaneously by the Participants in their respective countries and regions. 3. GOVERNANCE OF THE CALL AND EVALUATION PROCEDURE The governance of the call, its organization and the evaluation procedures are detailed in the document “Governance of the call and evaluation procedure” (i.e. Annex 1 to this MoU). All decisions concerning the JTC 2021 call procedures and transnational project funding will be taken by the Call Steering Committee (CSC) together with the European Commission. The Joint Call Secretariat (JCS) of JTC 2021 is organised by the French Foundation for Rare Diseases (FFRD), France. The responsibilities of the CSC and the JCS are detailed in the document “Governance of the call and evaluation procedure”. The scientific assessment of applications will be led by a Scientific Evaluation Committee (SEC) on the basis of scientific quality and evaluation criteria as specified in the document “Governance of the call and evaluation procedure”. The CSC will select proposals for funding according to the reviews and the final ranking list established by the SEC. Subsequently the final decision will be made by the respective 4 EJP RD JTC 2021: MoU national/regional funding organisations subject to availability of funds and in compliance with applicable regulations and legal provisions. A two-stage submission and evaluation procedure for joint proposals with a rebuttal stage will be applied. 4. ELIGIBILITY OF APPLICATIONS The eligibility of institutions, patient organisations and costs, as well as complementary administrative requirements are subject to the country and/or regional Participant’s regulations and legal framework and may therefore vary from one Participant to another. Information needs to be provided on time and form according to relevant Participant’s regulations for research funding. The general eligibility rules for this call are specified in the call text and the national/regional criteria in the guidelines document. 5. FUNDING BUDGETS AND PROCEDURES The envisaged contribution by each Participant is listed below as follow: Envisaged amount of Country/Region Participant funding (M€ for 3 years) is up to: Austria FWF 0.6 Belgium/Flanders FWO 0.35 Belgium/French F.R.S.-FNRS 0.24 speaking community CIHR-IG, in partnership with Ataxia Canada Charlevoix-Saguenay Foundation $1.5 CAD and Muscular Dystrophy Canada Estonia MoSAE 0.075 France ANR 2 Germany BMBF 3 Hungary NKFIH 0.2 Israel CSO/MOH 0.2 Italy MoH-IT 0.5 Italy RT/TuscReg 0.3 Lithuania LMT 0.1 5 EJP RD JTC 2021: MoU Luxembourg FNR 0.3 Poland NCBR 0.6 Slovakia SAS 0.12 Spain ISCIII 0.5 Switzerland SNSF 0.56* Turkey TUBITAK 0,3 Multinational, funding INSERM 0.3 for PAO *The SNSF has earmarked a budget of 0.6 Mio Swiss Francs over three years (currently equivalent to 0.56 Mio. €) The funds provided by the Participants to this MoU (table above) will be used for research projects carried out by research centres and institutions according to their respective countries’ regulations and legal framework and based on the scientific quality of the proposals reflected by the SEC evaluation decision. The proposals will be funded in accordance with the ranking order as a result of the SEC advice, starting with the top-scoring proposals. In order to avoid early funding gaps, each Participant participating in the joint call is asked to match as accurately and realistically as possible the financial demand from the proposals with the budget earmarked for the call. The final decision on funding will be made by the respective Participants involved in the application. The respective Participants will make their decision based on the information provided by the CSC and recommendations from the SEC. Selected projects will receive funding directly from the corresponding Participant’s subject to availability of funds and in compliance with applicable regulations and legal provisions. Funding will be awarded and administered according to the terms and conditions of responsible Participant taking into account all other applicable national/regional regulations and legal framework. 6. EU Budget The EU budget corresponds for this call to the remaining EU Top-Up budget from JTC2019 and JTC2020, after consultation and vote of the Board of Funders of JTC2019 and 2020. The EU budget assigned to this call is 389,775€ will be administrated by INSERM for funding of Patient Advocacy Organisations from participating countries. Exceptions: Estonian PAOs cannot be funded directly by INSERM. Participating Spanish patients organizations (PAOs) cannot be funded by ISCIII directly, PAOs could be financed via subcontracting, provided that they develop research 6 EJP RD JTC 2021: MoU activities and the criteria for subcontracting detailed in the Spanish Act 38/2003, of November 17th are fulfilled. PAOs from Italy applying in collaboration with IRCCS funded by the MoH-IT, can participate in a Consortium as a “collaborators” with their own funding or can be financed as “sub-contractors” through the IRCCS’s budget. In any case, they cannot be funded by INSERM directly with the budget left from the previous co-funded calls. This decision was made to avoid blocking situation in case of oversubscription for PAOs and allow the maximum funding of projects with PAOs involved (with a maximum amount of 25,000€ per projects for PAOs), and to ensure adequate patient participation in this very patient centric call. 7. REPORTING The coordinators of all funded projects must submit brief annual scientific project reports and a final scientific project report in the form of an online questionnaire. This monitoring will be the role of CSH-MOH, Israel, and FNRS, Belgium, which is responsible for the online monitoring system for the funded projects. In addition, each team may have to report to its funding organisation, in accordance with the respective national/regional funding organisations’ regulations. 8. CONFIDENTIALITY Information exchanged between Participants in the scope of the present MoU is deemed to be confidential within the funders of the JTC2021 unless stated otherwise in writing. In particular, the content of the proposals received under this call is deemed to be confidential, except for the lists of applications and lists of projects selected for funding. This commitment will survive the expiration or termination of this MoU but shall not apply for disclosure or use of information, if a Participant is required to disclose information in order to comply with applicable laws or regulations or with a court or administrative order. 9. TERM AND AMENDMENTS For each Participant, the MoU will come into force on the date of signature by the Participant’s authorized representative. It shall cover the entire funding period of the joint call research projects at least until all commitments are settled (expected to start early in 2022 and to last at least 3 years), except force majeure, and including any extension period to be specified later in writing. The MoU may be amended and modified by written agreement of all Participants. 10. GDPR The Participants will take all necessary measures to process personal data collected and/or received in the scope of the application of this MoU in compliance with 7 EJP RD JTC 2021: MoU personal data protection rules and laws applicable to them. For participants within the European Union, this includes Regulation (EU )2016/679 of the European Parliament and the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) included. 11. ANNEXES List of annexes to this MoU: Annex 1: EJP RD JTC 2021 Call Steering Committee (CSC) composition Annex 2: Details on the implementation of the joint call are outlined in the document “Governance of the call and evaluation procedure” 12. SIGNATURES 8 EJP RD JTC 2021: MoU For Research Foundation - Flanders (FWO), Flanders, Belgium NAME: Dr. Hans Willems POSITION: Secretary General Signatures: Date: 10 EJP RD JTC 2021: MoU For Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium NAME: Dr. Ir. Véronique Halloin POSITION: Secretary General F.R.S.-FNRS Signature: Date: Brussels, December 17th, 2020 11 EJP RD JTC 2021: MoU For Canadian Institutes of Health Research Institute of Genetics (CIHR-IG) NAME: Dr. Christopher McMaster POSITION: Scientific Director, CIHR Institute of Genetics Signature: Date: Dec 18, 2020 12 EJP RD JTC 2021: MoU For French National Research Agency (ANR), France NAME: Thierry Damerval POSITION: Président Directeur Général Signature: Date: 16/12/2020 1 EJP RD JTC 2021: MoU For Ministry of Health – Ministero della Salute (MOH-IT), Italy NAME: Dr. Gaetano Guglielmi POSITION: Head Office 3 Health Research, Deputy Director General - Directorate General for Health Research and Innovation Signature: Date: 18 • EUROPEAN JOINT PROGRAMME EJP RD JTC 2021: MoU 1'- RARE DISEASES For Slovak Academy of Sciences (SAS), Slovakia NAME: Prof. Pavol ŠAJGALíK POSITION: President Signoture: Date: ,~b, 12 . 2ó 2 O 23 EJP RD JTC 2021: MoU Código seguro de Verificación : GEN-f9e3-d192-79e8-39f6-c310-6fe9-d784-1526 | Puede verificar la integridad de este documento en la siguiente dirección : https://sede.administracion.gob.es/pagSedeFront/servicios/consultaCSV.htm For National Institute of Health Carlos III [Instituto de Salud Carlos III (ISCIII)]* Spain NAME: Dr. Raquel Yotti Álvarez POSITION: General Director Signature: Date: 25 *The funding commitment is subject to the approval of the General State Budget for 2021 CSV : GEN-f9e3-d192-79e8-39f6-c310-6fe9-d784-1526 DIRECCIÓN DE VALIDACIÓN : https://sede.administracion.gob.es/pagSedeFront/servicios/consultaCSV.htm FIRMANTE(1) : RAQUEL YOTTI ALVAREZ | FECHA : 30/11/2020 20:32 EJP RD JTC 2021: MoU For Swiss National Science Foundation (SNSF) NAME: Dr. Irene Knüsel POSITION: Head, Division Biology and Medicine, Swiss National Science Foundation Signature: Date: December 17, 2020 25 EJP RD JTC 2021: MoU For the French National Institute of Health and Medical Research (INSERM), France NAME: P/ Madame Camille Chaudonneret POSITION: Délégué Régionale Signature: Date: December 28, 2020 27 EJP RD JTC 2021: MoU ANNEX1: EJP RD JTC 2021 Call Steering Committee (CSC) composition  Austrian Science Fund (FWF), Austria Representative Name: Dr. Stephanie Resch Position: Scientific officer Proxy Name: Anita Stuertz, Dipl.-Ing. Position: Operational Project Officer  Research Foundation - Flanders (FWO), Flanders, Belgium Representative Name: Alain Deleener Position: Science Policy Advisor Strategic Research Programmes Proxy Name: Toon Monbaliu Position: Advisor Research Affairs  Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium Representative Name: Florence Quist Position: Scientific officer Proxy Name: Joël Groeneveld Position: Senior Policy officer  Canadian Institutes of Health Research (CIHR-IG), Canada Representative Name: Etienne Richer Position: Proxy Name: Marilyn Desrosiers Position: Deputy Director, Strategic Program Design and Analytics, CIHR 28 EJP RD JTC 2021: MoU  Ministry of Social Affairs (MoSAE), Estonia Representative Name: Heli Paluste Position: Head of Health Care Unit Proxy Name: Mari Teesalu Position: Research Adviser for Health Policy  French National Research Agency (ANR), France Representative Name: Dr. Florence Guillot Position: Scientific Coordinator  Federal Ministry of Education and Research (BMBF), Germany Representative Name: Dr. Ralph Schuster Position: Scientific officer Proxy Name: Dr. Katarzyna Saedler Position: Scientific officer Name: Dr. Michaela Fersch Position: Scientific officer  National Research, Development and Innovation Office (NKFIH), Hungary Representative Name: Dr. Gábor Tóth Position: Head of Unit, Unit for Medical and Biological Sciences Proxy 29 EJP RD JTC 2021: MoU Name: Dr. Előd Nemerkényi Position: Assistant of International Affairs  Chief Scientist Office, Ministry of Health (CSO-MOH), Israel Representative Name: Prof. Avi Israeli Position: Chief Scientist Proxy Name: Dr. Irit Allon Position:  Ministry of Health – Ministero della Salute (MOH), Italy Representative Name: Dr. Gaetano Guglielmi Position: Head Office 3 (Health Research – IRCCS) Proxy Name: Dr. Monica Paganelli – Dr. Raffaele Ruocco Position: Scientific Officers  Tuscany Region (RT/TuscReg), Tuscany (Italy) Representative Name: Donatella Tanini Position: Proxy Name: Teresa Vieri Position:  Research Council of Lithuania (LMT), Lithuania Representative Name: Živilė Ružele Position: Chief Officer Proxy Name: Jūratė Devižienė Position: Head of International Programmes Unit 30 EJP RD JTC 2021: MoU  National Research Fund (FNR), Luxembourg Representative Name: Sean Sapcariu Position: Programme Manager Proxy Name: Marie-Claude Marx Position: Programme Manager  National Centre for Research and Development (NCBR), Poland Representative Name: Marcin Chmielewski Position: Programme officer  Slovak Academy of Sciences (SAS), Slovakia Representative Name: Zuzana Cernakova, PhD Position: Programme officer Proxy Name: Ing. Katarina Bibova Position: Programme officer  National Institute of Health Carlos III (ISCIII), Spain Representative Name: Ignacio Baanante Position: Head of the EU and Internationalization Division [EU+Int] Proxy Name: Gonzalo Arévalo Position: Deputy General Director for International Research Programmes and Institutional Relations  Swiss National Science Foundation (SNSF), Switzerland Representative Name: Dr. Florence Ettlin Position: Scientific officer 31 EJP RD JTC 2021: MoU  The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey Representative Name: Dr. Jale Şahin Position: Programme officer  The French National Institute of Health and Medical Research (INSERM), France Funding Patient Advocacy Organisation Representative Name: Dr. Daria Julkowska Position: Programme officer 32
Allikas: Sotsiaalministeerium dokumendiregister →